NewsRoom Articles - Page 517 of 587

TuesdayAug 14, 2018 11:31 am

Earth Science Tech, Inc. (ETST) Pursues Multi-National Development of CBD Formulations, Hemp-Based Superfood and Home Testing Kit

In Canada and Brazil, ETST is lab testing three new cannabidiol formulations, developing two more CBD products and conducting studies on its Hygee device for women In the U.S., it is researching CBD’s impact on breast cancer and immune cells ETST is focused on the development of innovative products to reach its goal of becoming a world leader in the CBD space, with three new CBD formulas being developed under a provisory patent Earth Science Tech, Inc. (OTC: ETST) is testing in Canada and Brazil a diverse mix of cannabidiol (CBD) formulations, including a superfood formula (http://cnw.fm/9tTZ1). It is also conducting…

MondayAug 13, 2018 12:09 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is Named for its Attention to Preventative Health Care

Private placement of $4.9 million in June 2018 Five R&D programs currently underway Preventative health care market set to reach $200 billion by 2025 PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it…

MondayAug 13, 2018 11:36 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Human Clinical Study on TurboCBD Capsules Corroborates Earlier DehydraTECH Test Results

Significant bioavailability results were reported from LXRP’s randomized, double-blind European study that evaluated its proprietary TurboCBD capsules, powered by DehydraTECH Results corroborate and confirm in vitro and in vivo studies of DehydraTECH technology that measured high levels of drug delivery being achieved faster than with matching controls LXRP says that it is pleased that DehydraTECH has, to date, repeatedly proved evidence of success within human studies; technology earlier demonstrated ability to deliver nicotine Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is pleased to report significant bioavailability results from its randomized and double-blind European human clinical study of DehydraTECH™ powered TurboCBD™…

MondayAug 13, 2018 10:50 am

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) Investee Companies Gain Traction in US Medical Cannabis Space

FinCanna’s royalty finance model could be a game changer for companies needing capital while operating in the U.S. medical cannabis space Pilot marketing program offering HIPAA-compliant point-of-sale solution and inventory tracking system launched in California’s medical cannabis marketplace The U.S. medical cannabis market is projected to grow at 11.8 percent CAGR through 2025 from $5.1 billion to an estimated $12.5 billion in 2025 (New Frontier Data) FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF), a royalty company focused on becoming the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry, continues to gain momentum…

FridayAug 10, 2018 2:37 pm

Cannabis Strategic Ventures, Inc. (NUGS) Prepares to Uplist with Renewed Focus on Financial Reporting

Cannabis Strategic Ventures working toward fully reporting status with SEC, OTC exchange Company’s portfolio includes professional staffing services, high-quality cannabis oils Cannabis industry expected to be responsible for more than 600,000 jobs by 2025 Cannabis Strategic Ventures, Inc. (OTC: NUGS) has pursued its mission to foster legalized cannabis industry value-adds by building a portfolio of vertically integrated companies, and now the company is preparing to uplist on the public markets by refocusing its efforts on bringing its financial reporting up to par. “While building on our business portfolio is very important to us, bringing the Company up to fully reporting…

FridayAug 10, 2018 12:09 pm

ChineseInvestors.com, Inc.’s (CIIX) CBD Division Holds Promise, as Detailed in MoneyTV Interview

CBD division offers potential for shareholders, as shared on MoneyTV Over 70 retail establishments offering ChineseHempOil.com products in Los Angeles Ground work for wholly owned subsidiary focused on CBD products began in 2016 Continued commitment to cryptocurrency education for the Chinese-speaking community worldwide ChineseInvestors.com, Inc. (OTCQB: CIIX), a company focused on providing financial information and services to the Chinese-speaking community worldwide, will soon spin off its cannabis-related products into the wholly owned subsidiary ChineseHempOil.com, Inc. The spinoff was originally scheduled for May 31, 2018, but was temporarily postponed as CIIX continues to develop domestic sales channels. CEO Warren Wang joined…

ThursdayAug 09, 2018 11:23 am

Earth Science Tech, Inc. (ETST) Thinking of the Future in the CBD Space

The company is working to be a major provider of premier CBD products ETST’S three subsidiaries focus on developing its role as a global leader in the CBD space ETST is forward-thinking – centering on the science, research and studies of its high-grade hemp CBD oil Based in Doral, Florida, Earth Science Tech, Inc. (OTC: ETST) is a biotechnology company with three wholly owned subsidiaries. Through these, it operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. CBD offered by the company is in the form of vitamins, minerals, herbs, botanicals, personal care…

WednesdayAug 08, 2018 12:58 pm

Investment Researchers Peg Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) as Example of ‘Badly Mispriced’ Stock with Return Potential

Beacon Securities Limited argues that Sunniva’s Canadian greenhouse alone is worth more than its entire market cap California facility, Canadian cannabis clinics add to company’s value Sunniva also bolstered by agreement with licensed producer Canopy Growth Corp. amid heightened M&A activity in cannabis sector Cannabis supplier Sunniva Inc.’s (CSE: SNN) (OTCQX: SNNVF) strengthening foothold in California’s and Canada’s consumer-populated markets has been failing to translate to its stock price and market cap since it began trading on the Canadian Securities Exchange and the U.S. OTCQX® Best Market in January, leading investment researchers at Beacon Securities Limited (http://cnw.fm/PhE2A) to classify Sunniva’s public offering as a…

WednesdayAug 08, 2018 11:56 am

Cannabis Strategic Ventures, Inc. (NUGS) Does Deal for Clean Cannabis as New Regulations Take Effect

New regulations mandate cleaner, safer cannabis Cannabis concentrate extraction deal with CGMP-compliant facility Launch of Pure Organix with vape pen cartridges Appointment of CPG-experienced board member The deal that Cannabis Strategic Ventures, Inc. (OTC: NUGS) recently struck with Sunniva Inc. comes at a crucial time in the California cannabis industry. On July 1, new, stricter regulations came into force that caused quite a kerfuffle; retailers were forced to sell off non-compliant products in what has been labelled a “fire sale” of cannabis. As the industry develops, California state authorities appear to be building a robust regulatory regime, which will put…

WednesdayAug 08, 2018 9:00 am

Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA

CannabisNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD). FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR What’s most transformative about this drug approval is that…

News and publishing service for cannabis related companies

Contact us: 512.354.7000